Pfizer Korea keen on domestic bioequivalence testing

Pfizer Korea, Korean unit of the world's biggest drugmaker, is keenly interested in this country’s bioequivalence testing to increase sales of medicines that have lost patent protection.

In a local symposium organized by the Korea Pharmaceutical Manufacturers Association on Tuesday, Pfizer Korea official Pyun Suk-wha said that Korea should apply more stringent standards of bioequivalence tes...